Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Tuberk Toraks ; 61(2): 115-21, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23875589

RESUMO

INTRODUCTION: Lung diseases caused by biomass exposure cause a significant health hazard particularly amongst women. The present study was designed to investigate biomass exposure in women suffering from lung disease. MATERIALS AND METHODS: A total of 100 women [mean (SD) age: 55.13 (17.65) years] hospitalized for chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, tuberculosis or interstitial lung disease were included in this study conducted between September 2008-March 2009 in three chest disease clinics at Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital. Data collection on biomass exposure was based on application of hospital-based survey questionnaire including items on occupation, level of education, place of birth (location, region), exposure to biomass fuel fumes for heating and cooking purposes (animal dung, wood, charcoal, dried plant) and years of exposure with animal dung, wood, charcoal, dried plant. RESULTS: COPD in 22% patients, lung carcinoma in 12%, bronchitis in 8%, tuberculosis in 26%, and interstitial lung disease in 17% were the diagnosis for hospitalization. The most identified occupation was housewifery 86%. Active, former and non-smokers composed 6%, 22% and 72% of the population. Birth place was village in 67% patients while districts in 9%. According to regional distribution, the most common place of birth was Central Anatolia region in (29%). Exposure to biomass fuels was identified in all of patients including wood (92%), animal dung (30%), charcoal (23%), and dry plant (23%). Mean (SD) years of exposure was identified to be 52.6 (17.9) years for wood, 40.8 (17.9) years for animal dung, 48.1 (20.8) years for dry plant and 38.5 (21.4) years for charcoal. The most common type of biomass exposure was wood in village (97%), city (79%) and county (89%). CONCLUSION: Findings indicating impact of biomass exposure in women seem to emphasize the need for analytic epidemiologic studies assessment measuring biomass exposure levels-particularly for women and young children.


Assuntos
Exposição Ambiental/efeitos adversos , Pneumopatias/etiologia , Fumaça/efeitos adversos , Biomassa , Carvão Vegetal , Culinária/métodos , Feminino , Substâncias Perigosas , Calefação , Humanos , Pneumopatias/epidemiologia , Pneumopatias/patologia , Pessoa de Meia-Idade , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Doença Pulmonar Obstrutiva Crônica/etiologia , Doença Pulmonar Obstrutiva Crônica/patologia , Madeira
2.
Tuberk Toraks ; 60(4): 344-9, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23289464

RESUMO

INTRODUCTION: To present the treatment outcome in tuberculosis patients with sputum smear positivity in the third month of category 1 treatment regimes. PATIENTS AND METHODS: A total of 1024 patients with tuberculosis treated in Ministry of Health Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital from January 2004 to December 2005 were included in this retrospective cohort study. Categorization and appropriate treatment of tuberculosis was performed according the World Health Organization guidelines. RESULTS: Of overall 1024 patients, 655 (64%) were determined to receive category 1 treatment while sputum smear positivity was identified in 11 of them [2%; mean (SD) age: 46 (17.9) years] in the third month. Continuation phase treatment was initiated in these 11 patients. Sputum conversion was evident in six of 10 cases in the 4th month, in three cases in the 5th month and in one case in the 6th month. None had culture positivity after the 3rd month. Of 11 cases, 10 completed therapy with major drugs in six months and treatment outcome was cure. No relapse was identified after five years later. CONCLUSION: Based on our data we recommend that the continuing phase should be started in cases with positive sputum smear at the end of the extended initial phase.


Assuntos
Antituberculosos/uso terapêutico , Avaliação de Resultados em Cuidados de Saúde , Escarro/microbiologia , Tuberculose Pulmonar/tratamento farmacológico , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
3.
Tuberk Toraks ; 60(1): 32-40, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22554364

RESUMO

INTRODUCTION: The present study was designed to determine the distribution of tuberculosis patients according to their occupations in Turkey. PATIENTS AND METHODS: A total of 757 patients with bacteriologically and histopathologically confirmed diagnosis of tuberculosis and under the tuberculosis treatment were included in this retrospective descriptive study. Medical records of patients admitted to the Ministry of Health Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital between the years of 2004 and 2007 were evaluated in terms of patient demographics and the occupations. Occupations were classified into 10 groups according to the International Standardization Classification Occupation (ISCO-88). RESULTS: Males composed 67% of the overall population [mean age (SD) was 41.3 (16.4) years]. Recurrent and newly diagnosed tuberculosis patients composed 81 and 19% of the patients, respectively. The most frequently identified major occupational groups were; craft and related workers (32%), plant and machine operators and assembler (10%), followed by the subgroups of textile, garment and related trades workers (12.9%), motor vehicle drivers (5.8%). The youngest subgroup among the most popular subgroups with a mean age (SD) of 29.5 (11.1) years, was textile, garment and related trades workers while the subgroup of mining and construction laborers was the oldest with a mean age (SD) of 63.9 (7.9) years. In all occupational subgroups, the frequency of males was higher than females. In female patients, the most frequently identified subgroup was, textile, garment and related trades workers while, mining and construction laborers, motor vehicle drives, building frame and related trades workers were composed solely of males. The frequency of newly diagnosed patients was significantly higher than former tuberculosis patients in the occupational subgroups. CONCLUSION: It seems crucial to improve conditions of workplaces with arrangements enabling healthier environment such as adequate ventilation, appropriate living space as well as routine health controls of employees especially for the textile industry.


Assuntos
Doenças Profissionais/epidemiologia , Ocupações/estatística & dados numéricos , Tuberculose/epidemiologia , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Profissionais/etiologia , Exposição Ocupacional/efeitos adversos , Estudos Retrospectivos , Distribuição por Sexo , Tuberculose/etiologia , Turquia/epidemiologia , Adulto Jovem
4.
Tuberk Toraks ; 60(2): 136-44, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22779934

RESUMO

INTRODUCTION: Hepatotoxicity is one of the most frequent adverse events occurring during tuberculosis treatment that may negatively affect treatment compliance, clinical outcome. This study was designed to evaluate management, risk factors related to hepatotoxicity during tuberculosis treatment. PATIENTS AND METHODS: Hospitalized patients for tuberculosis treatment at Sureyyapasa Chest Diseases, and Chest Surgery Training and Research Hospital were included, between January 2004 and December 2007. Prevalence of hepatotoxicity, risk factors were evaluated among tuberculosis patients under anti-tuberculosis treatment according to World Health Organization (WHO) guideline. Hepatotoxicity was defined any elevated liver function tests with accompanying symptoms. Age, gender, past history of anti-tuberculosis treatment, extensity of radiological findings, co-morbid disorders and drug resistance were the risk factors evaluated in terms of development and recurrence of hepatotoxicity. RESULTS: Of 1443 patients (38.37 ± 16.74 years; 64.5% were males), 106 (7.3%) was identified to develop hepatotoxicity on an average of 20 days after beginning treatment and lasting an average of 14 days. Hepatotoxicity for once in 78.3% (n= 83) of patients and more than once in 21.7% (n= 23) patients. All anti-tuberculosis drugs was continued at full dosage after the normalization of liver enzyme in 76.4% (n= 81). In recurrence a step-by-step treatment was re-started by exclusion of responsible drug/s. Treatment was administered without modification of WHO regimes in 79.2%. Pyrazinamide was omitted in 15 cases while rifampicin only in one patient. Triple drug regimen with isoniazid, ethambutol and streptomycin was used in six cases. Quinolon was added to treatment only in one patient. Presence of a co-morbidity was determined to be significant predictor of hepatotoxicity development OR= 3.093 (CI= 1.95-4.89; p= 0.000) past history of anti-tuberculosis treatment was significantly associated with recurrence (p= 0.027). There was no hepatotoxicity dependent mortality. CONCLUSION: Hepatotoxicity can be successfully management of hepatotoxicity without second line tuberculosis drugs in ongoing treatment regime.


Assuntos
Antituberculosos/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Tuberculose Pulmonar/tratamento farmacológico , Adulto , Fatores Etários , Antituberculosos/uso terapêutico , Doença Hepática Induzida por Substâncias e Drogas/epidemiologia , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Comorbidade , Farmacorresistência Bacteriana , Quimioterapia Combinada , Feminino , Humanos , Isoniazida/efeitos adversos , Isoniazida/uso terapêutico , Testes de Função Hepática , Masculino , Pirazinamida/efeitos adversos , Pirazinamida/uso terapêutico , Recidiva , Rifampina/efeitos adversos , Rifampina/uso terapêutico , Fatores de Risco , Fatores Sexuais , Resultado do Tratamento
5.
Int J Mycobacteriol ; 11(4): 442-447, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36510932

RESUMO

Aim: Increasing the extensity of latent tuberculosis infection (LTBI) treatment which is one of the important parameters of tuberculosis (TB) control and completing the treatment in success are important. The purpose of this study is to evaluate LTBI treatment indications and treatment outcomes of patients who received LTBI treatment in Istanbul between 2016 and 2018. Methods: The treatment outcomes of people who started LTBI treatment registered in TB dispensaries in Istanbul between 2016 and 2018 were analyzed retrospectively according to the variables of the age groups, gender, dispensary subgroups, and prevention treatment indications. Data collected from the health institutions were evaluated. Results: 26.920 patients received LTBI treatment in all Istanbul TB dispensaries between 2016 and 2018. The evaluation of LTBI treatment indications; contact 15.696, Tuberculin skin test (TST) positivity 2224, immunosuppression 8746, TST conversion 58, sequelae lesion 15, and other indications are identified as 181. The groups which diagnosed with TB disease, mortality, transfer, other, and still in treatment are excluded from the analysis of LTBI treatment outcomes. A total of 25.253 patients were analyzed. 65 percent of the patients had completed LTBI treatment. Variables effective for treatment outcomes are analyzed with logistic regression. Treatment discontinuation was statistically significantly lower in 2017 (odds ratio [OR]: 0.906 confidence interval [CI] [95%] [0.849-0.968]) and 2018 (OR: 0.635 CI [95%] [0.594-0.679]) compared to 2016. Treatment lost to follow-up was statistically significantly lower in those receiving LTBI treatment with the indication of tuberculin skin test positivity (OR: 0.541 CI [95%] [0.487-0.600]) and the indication of immunosuppression (OR: 0.284 CI [95%] [0.142-0.569]) compared to those who received LTBI treatment due to contact. When the treatment results are evaluated according to the TB incidence of the region where the dispensaries are located, treatment lost to follow-up was higher in 101-200 per 100,000 incidence group (OR: 1.201 CI [95%] [1.123-1.285]) and incidence of 201-370 per 100,000 (OR: 1.461 CI [95%] [1.358-1.572]). Treatment lost to follow-up was higher in dispensaries on the European side (OR: 1.293 CI [95%] [1.203-1389]) and the 0-35 age group (OR: 1.248 CI [95%] [1.168-1.333]). Conclusion: In conclusion, the treatment completion rate should be improved for an effective LTBI treatment which is one of the important parameters of targeted TB elimination. Particularly people under the age of 35 years and regions with high-TB incidence should receive special care and close follow-up.


Assuntos
Tuberculose Latente , Tuberculose , Humanos , Adulto , Tuberculose Latente/diagnóstico , Tuberculose Latente/tratamento farmacológico , Tuberculose Latente/epidemiologia , Teste Tuberculínico/métodos , Testes de Liberação de Interferon-gama/métodos , Estudos Retrospectivos , Tuberculose/diagnóstico , Tuberculose/tratamento farmacológico
6.
Balkan Med J ; 30(2): 204-10, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25207101

RESUMO

BACKGROUND: Tuberculosis is a public health problem and its transmission is a threat to the community. AIMS: The aim of this study was to determine the factors influencing the treatment outcomes and the effectiveness of the National Tuberculosis Program (NTP) in relation to the application of the directly observed treatment, short-course (DOTS) program in various sites in Istanbul, Turkey. STUDY DESIGN: Case-Control Study. METHODS: A case-control study was used, where cases and controls were randomly selected from the Turkish Tuberculosis National Database, which includes complete data on treatment outcomes for patients recorded in the database from January 1, 2006 to December 31, 2009 and had one year follow-up. RESULTS: The case group was composed of 464 patients with adverse outcome, while the control group was composed of 441 patients who had been cured of disease. Factors associated with adverse treatment outcome were >65 years of age (OR: 3.39 (1.99-5.76)) ; male gender (OR:2.11 (1.49-2.99)); born outside Turkey (OR: 5.48 (2.13-14.04)); co-morbidity (OR: 1.85 (1.29-2.65)); bilateral radiologic lesions (OR: 2.07 (1.41-3.00); previous treatment history (OR: 3.99 (2.78-5.74)); 3(rd) month positive microscopy (OR: 4.96 (3.04-8.09)) and any H&R +/- others multidrug resistant (MDR) resistance (OR: 22.64 (6.92-74.08)). There was no association between the adverse treatment outcome and the application site of direct observation treatment, short course (DOTS) delivery and the supervisors. CONCLUSION: Our findings indicate similar quality in DOTS application and supervision among patients with or without adverse treatment outcomes. However, patients with certain characteristics should be carefully monitored and aggressively treated.

7.
J Bronchology Interv Pulmonol ; 17(1): 80-3, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23168667

RESUMO

A 24-year-old woman presented with chronic cough and noisy breathing. Chest x-ray revealed diffuse irregularity and narrowing of the tracheal lumen. Thorax computed tomography showed irregularity, stenosis, and areas of ossification throughout the trachea and both main bronchia. Flexible bronchoscopy revealed multiple nodules protruding into the tracheal lumen. Histopathology of the nodules confirmed the diagnosis of "tracheobronchopathia osteochondroplastica." Tracheobronchopathia osteochondroplastica is a rare, benign disease that is characterized by multiple cartilaginous and osseous submucosal nodules protruding through tracheal lumen and large bronchia. The etiology is still unexplained.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA